Wang 2008.

Methods	Allocation: randomised. Blindness: not stated. Duration: 6 weeks.
Participants	Diagnosis: schizophrenia (CCMD‐3). N = 60. Age: average ˜ 28 years (SD ˜ 9). Sex: 29 men 31 women. History: average duration ill ˜ 7 years (SD ˜ 5). Inclusion criteria: With permission from patients and their families. Exclusion criteria: Serious physical diseases; brain organic mental disorders; drug abuse; pregnancy and women who were lactating; drug allergy.
Interventions	1. WDD (please see details in Table 5) + clozapine: dose clozapine, 100 mg/d to 200 mg/d. N = 31. 2. Clozapine: dose clozapine, 250 mg/d to 550 mg/d. N = 29.
Outcomes	Global state: cure (binary PANSS scores ‐ reduced >75%, 50% to 74%, 25% to 49%, no effect ‐ <24%). Mental state: PANSS total.* Adverse events: EPS, salivation, constipation, drop in blood pressure, headache and dizziness, weakness, exciting, indigestion, insomnia (TESS).
Notes	*: PANSS at 2 and 4 weeks after treatment not used in this review (short‐term data used 6‐week outcomes).
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "randomly divided in to intervention group and control …"
Allocation concealment (selection bias)	Unclear risk	Not stated.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Not stated.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not stated.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No missing outcome data.
Selective reporting (reporting bias)	Low risk	We were unable to locate original study protocol, however, all outcomes listed in the 'methods' section of the paper appear to have been measured and reported.
Other bias	Low risk	No obvious other bias.